Aurinia Pharmaceuticals (AUPH) AI Stock Analysis

• Market Cap: $1.01B
• Dividend Yield: N/A
• Average Volume (3M): 1.32M
• Price to Earnings (P/E): 27.1
• Beta (1Y): 0.98
• Revenue Growth: 29.20%
• EPS Growth: N/A
• Country: US
• Employees: 130
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): 0.16
• Shares Outstanding: 135,104,310
• 10 Day Avg. Volume: 1,810,728
• 30 Day Avg. Volume: 1,324,258
• PEG Ratio: 0.12
• Price to Book (P/B): 1.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.68
• Enterprise Value/Market Cap: 0.52
• Enterprise Value/Revenue: 0.58
• Enterprise Value/Gross Profit: 2.41
• Enterprise Value/Ebitda: 9.04
• 1Y Price Target: $9.75
• Price Target Upside: 30.17% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 69 Neutral
• Price Target: $8.00 ▲(6.81%Upside)

Aurinia Pharmaceuticals benefits from strong financial performance and positive earnings highlights, driving a solid overall score. However, technical indicators suggest bearish momentum, and valuation metrics indicate moderate attractiveness. Risks from patent litigation and market competition introduce uncertainty.

Positive Factors

Earnings

Aurinia reported 1Q-2025 results beating estimates.

Financial Position

The company generated $23.3M in net income and ended the period with $312.9M in cash, indicating a strong financial position.

Product Performance

Lupkynis product revenue came in ahead of estimates, increasing 25% year-over-year.

Negative Factors

Sales Force

Conservative range could be result of a downsized sales force.

Sales Guidance

Sales guidance for FY25 is within expectations but below consensus.

Strategic Position

Disappointment that Aurinia will remain standalone, as more value could have been created with strategic synergies within a more established commercial organization.

Aurinia Pharmaceuticals Business Overview & Revenue Model

Company Description

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies to treat autoimmune diseases. Based in Victoria, British Columbia, Canada, Aurinia is primarily engaged in the development of its lead drug, Lupkynis (voclosporin), which is used for the treatment of lupus nephritis, a serious complication of the autoimmune disease systemic lupus erythematosus (SLE). The company's mission is to improve the lives of patients living with debilitating autoimmune conditions through innovative therapeutics.

How the Company Makes Money

Aurinia Pharmaceuticals generates revenue primarily through the sales of its FDA-approved drug, Lupkynis. The company markets this drug mainly in North America, and it is designed to treat patients with active lupus nephritis. Aurinia also seeks revenue through partnerships and collaborations with other pharmaceutical companies to expand the reach and application of its products. Additionally, the company may receive milestone payments and royalties as part of licensing agreements with other entities involved in the development and commercialization of its drug. These partnerships and collaborations play a significant role in the company's financial growth and market expansion.

Aurinia Pharmaceuticals Financial Statement Overview

Summary

Aurinia Pharmaceuticals demonstrates strong financial performance with significant revenue growth, improved profitability, a stable balance sheet with low leverage, and robust cash flows. The company is on a positive trajectory, although maintaining growth and operational efficiency will be crucial as it navigates market challenges.

Income Statement

Aurinia Pharmaceuticals has shown impressive revenue growth, with Total Revenue increasing from $134.03 million in 2022 to $247.30 million TTM (Trailing-Twelve-Months) in 2025, reflecting a robust growth trajectory. The Gross Profit Margin and Net Profit Margin have significantly improved, indicating better operational efficiency and profitability. EBIT and EBITDA margins have turned positive in the TTM period, showcasing a strong recovery from past losses.

Balance Sheet

The balance sheet is solid with a Debt-to-Equity Ratio well under 1, indicating low leverage. The company's Return on Equity has improved due to positive Net Income, enhancing shareholder value. However, the Equity Ratio has decreased slightly, reflecting a more balanced asset and liability management.

Cash Flow

The company exhibits a positive trend in Free Cash Flow with significant growth, suggesting improved financial health. The Operating Cash Flow to Net Income Ratio shows strong cash generation relative to net earnings. The Free Cash Flow to Net Income Ratio also indicates that cash flows are robust in relation to profitability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	247.29M	235.13M	175.51M	134.03M	45.60M	50.12M
Gross Profit	218.22M	206.88M	161.37M	128.37M	44.51M	-209.00K
EBITDA	54.34M	31.73M	-63.05M	-103.65M	-177.44M	-102.92M
Net Income	39.84M	5.75M	-78.02M	-108.18M	-180.97M	-102.68M
Balance Sheet
Total Assets	504.85M	550.64M	548.06M	470.86M	543.37M	463.66M
Cash, Cash Equivalents and Short-Term Investments	312.90M	358.48M	350.49M	389.39M	466.08M	398.33M
Total Debt	77.91M	79.37M	97.61M	8.09M	8.74M	8.41M
Total Liabilities	154.66M	173.17M	170.11M	65.42M	64.28M	55.91M
Stockholders Equity	350.19M	377.48M	377.95M	405.44M	479.09M	407.75M
Cash Flow
Free Cash Flow	64.02M	44.11M	-34.18M	-79.82M	-159.19M	-77.20M
Operating Cash Flow	64.29M	44.39M	-33.46M	-79.53M	-157.69M	-69.86M
Investing Cash Flow	20.99M	39.26M	-6.71M	-60.63M	-103.87M	-158.19M
Financing Cash Flow	-83.21M	-49.09M	-5.13M	2.43M	221.11M	194.38M

Aurinia Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.49
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUPH, the sentiment is Negative. The current price of 7.49 is below the 20-day moving average (MA) of 8.07, below the 50-day MA of 8.08, and below the 200-day MA of 8.03, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 37.76 is Neutral, neither overbought nor oversold. The STOCH value of 27.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AUPH.

Aurinia Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	69 Neutral	$1.01B	27.08	11.23%	―	29.20%	―
ARDX	57 Neutral	$933.10M	―	-36.26%	―	127.33%	21.31%
OCUL	55 Neutral	$1.45B	―	-57.19%	―	-0.33%	-3.59%
CLDX	52 Neutral	$1.41B	―	-23.20%	―	24.49%	5.14%
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
IOVA	48 Neutral	$581.05M	―	-51.85%	―	11070.12%	32.07%
LQDA	44 Neutral	$1.03B	―	-188.03%	―	-11.42%	0.26%

Aurinia Pharmaceuticals Corporate Events

Aurinia Pharmaceuticals Approves New Equity Incentive Plan

At the annual general meeting held on May 15, 2025, Aurinia Pharmaceuticals‘ shareholders approved an amended Equity Incentive Plan and revised Bylaws allowing shareholders to set the number of directors. The meeting also resulted in the election of several board members and the approval of PricewaterhouseCoopers LLP as the company’s independent accounting firm. These changes are expected to enhance corporate governance and align executive compensation with shareholder interests.

The most recent analyst rating on (AUPH) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.